

Open access • Posted Content • DOI:10.1101/2020.08.31.261214

Population Structure Discovery in Meta-Analyzed Microbial Communities and Inflammatory Bowel Disease — Source link 🖸

Siyuan Ma, Dmitry Shungin, Himel Mallick, Melanie Schirmer ...+6 more authors

Institutions: Harvard University, Broad Institute

Published on: 31 Aug 2020 - bioRxiv (Cold Spring Harbor Laboratory)

Topics: Microbiome and Human microbiome

Related papers:

- A hierarchical Bayesian approach for detecting global microbiome associations
- A Bayesian Multi-Task Approach for Detecting Global Microbiome Associations
- · A Novel Index for Predicting Health Status Using Species-level Gut Microbiome Profiling
- Decoding the language of microbiomes using word-embedding techniques, and applications in inflammatory bowel disease.
- Inflammatory Bowel Disease Biomarkers of Human Gut Microbiota Selected via Ensemble Feature Selection Methods.

Share this paper: 🚯 🄰 🛅 🖂

1 Population Structure Discovery in Meta-Analyzed Microbial

2

Communities and Inflammatory Bowel Disease

3	Siyuan Ma ^{1,2} , Dmitry Shungin ² , Himel Mallick ^{1,2} , Melanie Schirmer ² , Long H. Nguyen ³ ,
4	Raivo Kolde ² , Eric Franzosa ^{1,2} , Hera Vlamakis ² , Ramnik Xavier ^{2*} , Curtis Huttenhower ^{1,2*}
5	¹ Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
6	² Broad Institute of MIT and Harvard, Cambridge, MA, USA
7	³ Massachusetts General Hospital, Boston, MA, USA

8 Abstract

9 Microbial community studies in general, and of the human microbiome in inflammatory bowel 10 disease (IBD) in particular, have now achieved a scale at which it is practical to associate features 11 of the microbiome with environmental exposures and health outcomes across multiple large-scale 12 populations. This permits the development of rigorous meta-analysis methods, of particular 13 importance in IBD as a means by which the heterogeneity of disease etiology and treatment 14 response might be explained. We have thus developed MMUPHin (Meta-analysis Methods with 15 a Uniform Pipeline for Heterogeneity in microbiome studies) for joint normalization, meta-analysis, and population structure discovery using microbial community taxonomic and functional profiles. 16 17 Applying this method to ten IBD cohorts (5,151 total samples), we identified a single consistent 18 axis of microbial associations among studies, including newly associated taxa such as 19 Acinetobacter and Turicibacter detected due to the sensitivity of meta-analysis. Linear random 20 effects models further revealed associations with medications, disease location, and interaction 21 effects consistent within and between studies. Finally, multiple unsupervised clustering metrics

and dissimilarity measures agreed on a lack of discrete microbiome "types" in the IBD gut
 microbiome. These results thus provide a benchmark for consistent characterization of the IBD
 gut microbiome and a general framework applicable to meta-analysis of any microbial community
 types.

26 Introduction

27 Meta-analysis for molecular epidemiology in large populations has seen great success in linking 28 high-dimensional 'omic features to complex health-related phenotypes. One example of this is in 29 genome-wide association studies (GWAS¹), where the appropriate study scale, achieved by 30 rigorous integration of multiple cohorts, has both facilitated reproducible discoveries (in the form 31 of disease-associated loci²⁻⁴) and addressed confounding due to unobserved population 32 structure⁵. The inflammatory bowel diseases (IBD) represent a particular success story for GWAS 33 meta-analysis^{3,4}, and environmental and microbial contributors complementing the condition's complex genetic architecture have been detailed by many individual studies⁶⁻⁸. However, in the 34 35 absence of methods appropriate for large-scale microbial meta-analysis, the extent to which these 36 findings reproduce across studies, or can be extended by increased joint sample sizes, remains 37 undetermined. Likewise, it is unclear whether reproducible population structure in the microbiome, 38 such as microbially-driven IBD "subtypes," exists to help explain the clinical heterogeneity of these conditions⁹. 39

Meta-analysis of microbial community profiles presents unique quantitative challenges relative to other types of 'omics data such as GWAS¹⁰ or gene expression¹¹. These include particularly strong batch, inter-individual, and inter-population differences, and statistical issues including zero-inflation and compositionality^{12,13}. Consequently, methods to correct for cohort and batch effects from other 'omics settings¹⁴⁻¹⁷ are not directly appropriate. Two recent studies have suggested quantile normalization¹⁸ and Bayesian Dirichlet-multinomial regression (BDMMA)¹⁹ for

46 microbial profiles, which are applicable to a limited subset of differential abundance tests and do
47 not provide batch-corrected profiles. To date, there are no methods permitting the joint analysis
48 of batch-corrected microbial profiles for most study designs.

IBD represents one of the best-studied, microbiome-linked inflammatory phenotypes to date
 which thus stands to benefit from such approaches^{20,21}. Among the inflammatory bowel diseases,

51 Crohn's disease (CD) and ulcerative colitis (UC) have been individually linked with structural and 52 functional changes in the gut microbiome in many individual studies²¹. Each of CD and UC can 53 itself be highly heterogeneous within the IBD population, however, and diversity in disease-54 associated gut microbial features has not been consistently associated with factors including disease subtype, progression, or treatment response^{7,9,22,23}. Of note, two meta-analysis studies 55 included IBD as one of several phenotypes^{24,25}. These studies were not IBD-specific, did not have 56 57 access to appropriate normalization techniques, nor took the aforementioned factors into account. 58 The complexity of microbial involvement in IBD, and the presence of substantial unexplained 59 variation in the manifestation of its symptoms, makes it particularly appropriate for application of 60 meta-analysis techniques.


61 In this work, we introduce and validate a statistical framework for population-scale meta-analysis 62 of microbiome data, and apply it to the largest collection to date of ten published 16S rRNA gene 63 sequencing-based IBD studies (Table 1) to identify consistent disease associations and 64 population structure. We found both previously documented and novel microbial links to the 65 disease, with further differentiation among subtypes, phenotypic severity, and treatment effects. 66 We further confidently conclude that there are no apparent, reproducible microbiome-based 67 subtypes within CD or UC, which are instead a population structure gradient from less to more 68 "pro-inflammatory" ecological configurations. Our work thus represents one of the first large-scale

efforts to assesses consistency in gut microbial findings for IBD and provides methodologysupporting future microbial community meta-analyses.

71 Results

72 Integrating 10 studies of the IBD stool and mucosal microbiomes

73 We collected and uniformly processed ten published 16S studies of the IBD gut microbiome 74 (Table 1, Fig. 1a, Supplemental Table 1) totaling 2,179 subjects and 5,151 samples. These 75 studies range widely in terms of cohort designs and population characteristics, including recent-76 onset and established disease patients, cross-sectional and longitudinal sampling, pediatric and 77 adult populations, diseases (CD and UC), treated and treatment-naive patients, biopsy and stool 78 samples, and inclusion of healthy/non-IBD controls. Covariates were manually curated to ensure 79 consistency across studies (Methods). Major factors available from all or most studies included 80 demographics (age/sex/race), biogeography, disease location and/or extent, antibiotic usage, 81 immunosuppression, and steroid and/or 5-ASA usage.



83 Figure 1: A method for large-scale microbial community meta-analysis and its application to inflammatory 84 bowel disease. a) We developed a novel statistical framework, MMUPHin, allowing joint normalization and meta-85 analysis of large microbial community profile collections with heterogeneous and complex designs (multiple covariates, 86 longitudinal samples, etc.). We applied it to a collection of 10 inflammatory bowel disease studies comprising 2,179 87 subjects and 5,151 total samples (Table 1). We uniformly processed the associated sequence data and harmonized 88 metadata across cohorts. Microbial taxonomic profiles were then corrected for batch- and study-effects before 89 downstream analyses for omnibus and per-feature association with disease phenotypes and unsupervised population 90 structure discovery. b) MDS ordination of all microbial profiles (Bray-Curtis dissimilarity) before batch correction 91 visualize the strongest associations with gut microbial composition, including disease, sample type (biopsy or stool), 92 cohort (visualized separately for larger and smaller studies), and dominant phyla.

93 Using this joint dataset and upon uniform bioinformatics processing (**Methods**), we first assessed 94 the factors that corresponded to overall variation in microbiome structure, which included disease 95 status, sample type (biopsy versus stool), and dominant phyla (Bacteroidetes and Firmicutes, Fig. 96 **1b**). Cohort effects prior to batch correction and meta-analysis were also significant. Microbiome 97 differences associated with disease were notable even without normalization. However, this can 98 be misleading due to the confounding of cohort structure between studies, such as the 99 differentiation between RISK (a predominantly mucosal study of CD) and PROTECT (a 100 predominantly stool study of UC). Inter-individual differences largely independent of population or 101 disease, such as Bacteroidetes versus Firmicutes dominance, were also universal among studies and sample types as expected^{9,26}. Many of these factors were of comparable effect size, both 102 103 visually and as quantified below, emphasizing the need for covariate-adjusted statistical modelling 104 to delineate the biological (disease, treatment) and technical (cohort, batch) effects associated 105 with individual taxa throughout the cohorts (Supplemental Notes, Supplemental Fig. 1-3).

Study	Brief description	N	Ν	Phenotype(s)	Age	Gender	Sample
		subject	sample				type(s)
PROTECT	Longitudinal cohort	405	1212	UC 405	12.71	Male	Biopsy
23	of newly diagnosed		(539)		(3.29)	52%/	22%/
	UC					Female	Stool
						48%	78%

RISK ⁷	Pediatric cohort of	631	882	CD 430/	12.16	Male	Biopsy
NON.	treatment-naïve CD	001	002	Control 201	(3.22)	59%/	72%/
					()	Female	Stool
						41%	28%
Herfarth ²	Doncoly (daily)	31	860	CD 19/	36.03	Male	Stool
7	Densely (daily) sampled longitudinal	51	(31)	Control 12	(14.12)	35%/	51001
	cohort		(51)	CONTION 12	(14.12)	Female	
	conort					58%/	
						Missing	
						6%	
Jansson-	Longitudinal follow	137	683	CD 49/		Male	Stool
Lamende	up with fecal samples		(137)	UC 60/		42%/	
lla ²²				Control 28		Female	
						58%	
Pouchitis	Patients recruited	353	577	CD 42/	46.19	Male	Biopsy
28	underwent IPAA for			UC 266/	(13.58)	52%/	
	treatment of UC or			Control 45		Female	
	FAP prior to					48%	
	enrollment.						
CS-	Cross sectional	397	467	CD 215/	41.68	Male	Biopsy
PRISM ²⁹	cohort nested in			UC 144/	(15.22)	47%/	29%/
	PRISM			Control 38		Female	Stool
						53%	71%
HMP2 ⁹	Large cohort of newly	81	177	CD 37/	29.76	Male	Biopsy
	diagnosed IBD with		(162)	UC 22/	(19.63)	51%/	
	multi 'omics			Control 22		Female	
	measurement.					49%	
Mucosall	Pediatric cohort with	83	132	CD 36/	12.93	Male	Biopsy
BD ³⁰	Paneth cell		-	Control 47	(3.65)	58%/	- 7
	phenotypes				. ,	Female	
						42%	
LSS-	Longitudinal cohort	18	88 (19)	CD 12/	30.37	Male	Stool
PRISM ³¹	nested in PRISM.	10	<u> </u>	UC 6	(10.52)	39%/	5:501
					()	Female	
						61%	
BIDMC-	FMT Trial design	8	16	CD 8	38.38	Male	Stool
FMT ³²	i wi i i la design	J	10		(12.73)	62%/	51001
					(12.73)	Female	
						38%	

106 Table 1: 10 uniformly processed 16S rRNA gene sequencing studies of the IBD mucosal/stool microbiomes.

107 For longitudinal cohorts, numbers in parentheses indicate baseline sample size. For age, mean and standard error

108 (parenthesized) are shown. Additional covariates are summarized in **Supplemental Table 1**.

109 A statistical framework for meta-analysis of microbial community profiles


110 We developed a collection of novel methods for meta-analysis of environmental exposures, 111 phenotypes, and population structures across microbial community studies, specifically 112 accounting for technical batch effects and interstudy differences (Methods, Fig. 1a). It consists 113 of three main components: batch and study effect correction, covariate modeling, and population 114 structure discovery. First, we extended methods from the gene expression literature (ComBat¹⁵) 115 to enable batch correction of zero-inflated microbial abundance data. Based on linear modelling, 116 the method can differentiate between technical effects (batch, study) versus covariates of 117 biologically interest (exposure, phenotype). Second, we combined well-validated data transformation and linear modelling combinations for microbial community profiles³³ with fixed and 118 random effect modelling³⁴ for meta-analytical synthesis of per-feature (taxon, gene, or pathway) 119 120 differential abundance effects. Lastly, we generalized and formalized approaches from cancer transcriptional subtyping³⁵ to permit unsupervised discovery and validation of both discrete and 121 122 continuous population structures in microbial community data (Supplemental Fig. 4). Our 123 methods, implemented as Meta-analysis Methods with a Uniform Pipeline for Heterogeneity in 124 microbiome studies (MMUPHin), are available as an R package through Bioconductor³⁶ and at 125 https://bioconductor.org/packages/release/bioc/html/MMUPHin.html.

We validated MMUPHin both in comparison to existing methods and through extensive simulation studies (**Fig. 2**), with simulated realistic microbial abundance profiles at different data dimensionality, biological/technical batch signal strength, and discrete/continuous population structures (**Methods, Supplemental Table 2**, **Supplemental Fig. 5-8**). MMUPHin successfully reduced variability attributable to technical effects in simulated microbial profiles, as first quantified

by the PERMANOVA R2 statistic³⁷ (Fig. 2a-b, Supplemental Fig. 5). This was true both in terms 131 132 of reducing the overall microbial variability attributable to technical artifacts and in terms of the ratio of "biological" versus technical variability (Fig. 2a). ComBat correction¹⁵, suited for gene 133 134 expression data, was capable of reducing batch effects to a lesser degree, but also tended to 135 reduce desirable "biological" variation in the process, likely due to noise introduced by it changing 136 many zero counts to non-zero values. Previously proposed techniques for microbial community data, namely guantile normalization¹⁸ and BDMMA¹⁹, are only appropriate for differential 137 138 abundance analysis and do not provide batch-normalized profiles, thus precluding PERMANOVA 139 batch effect quantification; their per-feature testing performance is evaluated together with 140 MMUPHin in the following section. MMUPHin thus provides batch-corrected microbial community 141 profiles that retain biologically meaningful variation more than (or not even possible using) existing 142 methods.

143 For differential abundance testing, MMUPHin successfully corrected for false associations when 144 batch/cohort effects were confounded with variables of interest, which is a common concern for 'omics meta-analysis³⁸, while quantile normalization¹⁸ and BDMMA¹⁹ had either inflated or overly 145 146 conservative false positive rates (Fig. 2c-d, Supplemental Fig. 6). We also validated MMUPHin's 147 support for unsupervised population structure discovery, in addition to these "supervised" 148 differential abundance and statistical association tests. In microbial communities, valid, generalizable population structure can manifest as either discretely clustered subtypes³⁹ or as 149 continuously variable gradients of community configurations⁴⁰, but methods for discovery are 150 particularly susceptible to false positives in the presence of technical artifacts^{26,40}. To this end, for 151 discrete structures, MMUPHin utilizes established clustering strength evaluation metrics⁴¹ to a) 152 153 evaluate the existence of discrete clusters within individual microbiome studies and b) to validate 154 the reproducibility of such structures among studies meta-analytically (Fig. 2e-f, Supplemental 155 Fig. 7). For continuous structures, our method generalizes single study principal component

analysis (PCA⁴²) to multiple studies by constructing a network of correlated top PC loadings³⁵,
thus identifying major axes of variation that explain the largest amount of heterogeneity between
microbial profiles and are also consistent across studies (Fig. 2g-h, Supplemental Fig. 8). As a
result, MMUPHin was able to successfully identify discrete clusters (i.e. microbiome "types") when
present, as well as significantly consistent continuous patterns of microbiome variation that recur
among populations (Supplemental Notes).




163 Figure 2: Effectiveness of batch correction, association meta-analysis, and unsupervised population structure 164 discovery methods. All evaluations use simulated microbial community profiles as detailed in Methods. Left panels 165 summarize representative subsets of results (full set of simulation cases presented in Supplemental Table 2 and 166 results in **Supplemental Fig. 5-8**), and right panels show examples of batch-influenced data pre- and post-correction. 167 a, b) MMUPHin is effective for covariate-adjusted batch effect reduction while maintaining the effect of positive control 168 variables. Results shown correspond to the subset of details in Supplemental Fig. 5 with number of samples per batch 169 = 500, number of batches = 4, and number of features = 1000 with 5% spiked with associations. c, d) Batch correction 170 and meta-analysis reduces false positives when an exposure is spuriously associated with microbiome features due to 171 an imbalanced distribution between batches. Corresponds to Supplemental Fig. 6 with number of samples per batch 172 = 500, number of features = 1000 with 5% spiked associations, and case proportion difference between batches = 0.8. 173 Evaluations of BDMMA generates low FPRs due to the zero-inflated nature of simulated microbial abundances, and 174 are included only in Supplemental Fig. 6. e, f) Batch correction improves correct identification of the true underlying 175 number of clusters during discrete population structure discovery. Corresponds to Supplemental Fig. 7 with number 176 of batches = 4. g, h) Continuous structure discovery accurately recovers microbiome compositional gradients in a 177 simulated population. Corresponds to Supplemental Fig. 8 with number of batches = 6.

178 Meta-analysis of the IBD microbiome

179 Given these validations of MMUPHin's accuracy in simulated data, we next applied it to the 10-180 study, 4,789-sample IBD gut amplicon profile meta-analysis introduced above (Fig. 3). MMUPHin 181 successfully reduced the effects both of differences among studies, and of batches within studies 182 (study effect correction modelling disease and sample type as covariates, see **Methods**), 183 although these remained among the strongest source of variation among taxonomic profiles as 184 quantified by PERMANOVA R2 (Fig. 3a, Methods, Supplemental Table 3). Among biological 185 variables, sample type (biopsy/stool), biopsy location (multiple, conditional on biopsy samples), 186 disease status (IBD/control), and disease types (CD/UC, conditional on IBD) consistently had the 187 strongest effect on the microbiome among studies. Several relationships between study design 188 and phenotypic effects were apparent. Batches had a particularly strong effect in CS-PRISM and 189 RISK, for example, where biopsy and stool samples were also perfectly separated by batch.

190 Treatment exposures all had small effects on microbiome structure within studies, which typically 191 reached statistical significance only when combined by meta-analysis; antibiotics were an 192 exception with slightly larger effects. Montreal classification did not generally correspond with 193 significant variation, while age (at sample collection as stratified below and above 18, and at diagnosis by Montreal age classification⁴³) had small but significant effects. The effects of gender 194 195 and race were not significant. Lastly, for longitudinal studies, relatively stable differences between 196 subjects over time were large and significant, consistently for both longer-interval (HMP2) as well 197 as densely sampled cohorts (Herfarth, daily samples), in agreement with previous individual studies' observations^{9,23}. 198



200 Figure 3: Meta-analytic omnibus and per-feature testing reveal novel and previously documented IBD 201 associations. a) Omnibus testing (PERMANOVA on Bray-Curtis dissimilarities with stratification and covariate control 202 where appropriate, see Methods and Supplemental Table 3) identified between-subject differences as the greatest 203 source of microbiome variability, with IBD phenotype, disease (CD/UC), and sample type (stool/biopsy) as additional 204 main sources of biological variation. MMUPHin successfully reduced between-cohort and within-study batch effects, 205 although these technical sources also remained significant contributors to variability. b) Individual taxa significantly 206 associated with IBD phenotypes or treatments after meta-analysis. Taxa are arranged by family-level median effect 207 size of IBD vs. control for disease results and that of antibiotic usage for treatment results. Effect sizes are aggregated 208 regression coefficients (across studies with random effects modelling) on arcsin square root-transformed relative

abundances. Detailed model information in Methods and Supplemental Table 3. Individual study results in
 Supplemental Table 4.

211 We identified individual taxonomic features consistently associated with disease and treatment 212 variables (Fig. 3b, Supplemental Table 4), with meta-analysis multivariate differential 213 abundance analysis, adjusting for common demographics (age, gender, race) and further 214 stratifying for sample type and disease when appropriate (Methods, Supplemental Table 3). At 215 a very high level, differential abundance patterns between CD and control microbiomes were 216 consistent with, and often more severe than contrasts between UC and control, confirming with 217 increased resolution previous observations that CD patients tend to have more aggravated 218 dysbiosis than UC patients⁹. As expected, our meta-analysis confirms many of the taxa 219 associated with IBD reported by previous individual (Fig. 3b, detailed in Supplemental Notes); 220 these findings strongly supports the emerging hypotheses of pro-inflammatory aerotolerant 221 clades forming a positive feedback loop in the gut during inflammation, often of oral origin⁷, and 222 depleting the gut's typical fastidious anaerobe population as a result.


223 We also identified two taxa not previously associated with IBD, both of modest effect sizes and 224 likely newly detected by the meta-analysis' increased power. The genus Acinetobacter was 225 enriched in CD, and Turicibacter was depleted. Turicibater in particular is poorly represented in 226 reference sequence databases, with only nine genomes for one species (*Turicibacter sanguinis*) 227 currently in the NCBI genome database; this makes it easy to overlook in shotgun metagenomic 228 profiles relative to amplicon sequencing. The genus Acinetobacter, conversely, is quite well 229 characterized due to its role in antimicrobial resistant infections⁴⁴, and it was previously linked specifically to the primary sclerosing cholangitis phenotype in UC⁴⁵, although without follow-up to 230 231 our knowledge. Turicibacter is overall less characterized both in isolation and with respect to 232 disease, although our findings and others' suggest it might be inflammation-sensitive when present; it was one of many clades increased in mice during CD8+ T cell depletion⁴⁶ and reduced 233

in a homozygous TNF deletion⁴⁷. As the strains of *Acinetobacter* implicated in gut inflammation are unlikely to be those responsible for e.g. nosocomial infections, further investigation of both clades using more detailed data or IBD-specific isolates is warranted.

237 Among treatment variables (samples or time points during which subjects were receiving 238 antibiotics, immunosuppressants, steroids, and/or 5-ASAs), antibiotics had the strongest effects 239 on individual taxa, as well as the greatest number of significantly associated taxa (Fig. 3b). These 240 associations are also broadly in agreement with previous observations for microbiome responses 241 to antibiotics in IBD or generally, e.g. the depletion of Faecalibacterium, Ruminococcus, and 242 Bacteroides in patients treated with antibiotics, and the enrichment of (often stereotypically 243 resistant) taxa such as Streptococcus, Acinetobacter, and the Enterobacteriaceae, with 244 differential responses to the treatment groups speaking to both administration considerations and 245 their impact on host versus microbial community bioactivities (Supplemental Notes).

246 Subsets of IBD-linked taxa were additionally associated with the diseases' phenotypic severity (Fig. 4a, Supplemental Table 5). Montreal classification⁴³ was used as a proxy for disease 247 248 severity, including Behavior categories for Crohn's disease (B1 non-stricturing, non-penetrating, 249 B2 stricturing, non-penetrating, B3 stricturing and penetrating) and Extent for ulcerative colitis (E1 250 limited to rectum, E2 up to descending colon, E3 pancolitis). We tested for features differentially 251 abundant in the more severe phenotypes when compared against the least severe category (B1 252 CD and E1 UC, Methods). Among statistically significant results, many extended those identified 253 above as overall IBD associated (Fig. 3b), such as the depletion of *Faecalibacterium* in B3 CD 254 and Roseburia in B2 CD, as well as the enrichment of Enterobacteriaceae in E3 UC. In most 255 cases, microbial dysbiosis was also additionally aggravated from the moderate to the most 256 extreme disease manifestations; such differences were statistically significant (Methods) in, for 257 example, the progressive depletion of Bacteroides in CD and UC, as well as the enrichment of 258 Enterobacteriaceae in UC. This meta-analysis is uniquely powered to detect these subtle

differences, which aid in shedding light on the microbiome's response to progressive inflammation
 and disease subtypes. Pancolitis corresponds with a unique microbial configuration distinct from
 regional colitis and not generally detectable in smaller studies⁶, for example, while more severe
 CD induces essentially a more extreme form of the same dysbiosis observed in less severe forms
 of the disease.



265 Figure 4: IBD-associated taxa are aggravated in more severe disease; disease biogeography and CD/UC 266 differentially affect some taxa with respect to disease and treatment. a) Statistically significant genera from meta-267 analytically synthesized differential abundance effects among severity of CD and UC phenotypes as quantified by 268 Montreal classification. The difference between the most severe phenotype with the least severe one (B3 vs. B1 for 269 CD, E3 vs. E1 for UC) was in most cases more aggravated than that of the intermediate phenotype. Many of the 270 identified features overlap with those associated with IBD vs. control differences, suggesting a consistent gradient of 271 severity effects on the microbiome. Individual study results in Supplemental Table 5. b) Genus Dehalobacterium as 272 an example in which a taxon is uniquely affected in the stool microbiome during CD and not at the mucosa. Likewise, 273 family Enterobacteriaceae as an example in which steroid treatment corresponds with enrichment of the clade in CD


samples, but depletion in UC. In all panels, effect sizes are aggregated regression coefficients on arcsin square root transformed relative abundances. Full sets of statistically significant interactions, with individual study results, are in
 Supplemental Table 6.

277 Additionally, diseases (CD and UC) and their corresponding dysbioses also interacted distinctly 278 with the microbiome under different treatment regimes and in different biogeographical 279 environments (mucosa vs. stool, Fig. 4b, Supplemental Table 6). Interaction effects, in the 280 statistical sense, were defined as a main exposure (IBD or treatment) having differential effects 281 on taxon abundance with respect to either sample type (biopsy/stool) or diseases (CD/UC); they 282 were identified via moderator meta-analysis models (Methods). Overall, we found elevated 283 effects of both CD (relative to controls) and antibiotic treatment in stool as compared to biopsy-284 based measurements of the microbiome (Supplemental Table 6). An example of this is 285 Dehalobacterium, with significantly greater depletion in CD stool relative to biopsies (Fig. 4b). 286 Dehalobacterium, as with Turicibacter above, is underrepresented in reference sequence 287 databases, better-detected by amplicon sequencing, and thus not a common microbial signature 288 of IBD. It has been linked to CD in at least one existing 16S-based stool study⁴⁸. In contrast, 289 several UC-specific microbial disruptions were more prominent at the mucosa (i.e. in biopsies, 290 Supplemental Table 6). Coupled with the severity-linked differences above, this suggests CD-291 induced changes in the entire gut microbial ecosystem largely as a consequence of inflammation, 292 with UC-induced dysbioses both more local and more specific to disease and treatment regime. 293 Additional results include effect of steroids on the Enterobacteriaceae, which tended to be more 294 abundant in CD patients receiving steroids, but less abundant in UC recipients (Fig. 4b, 295 Supplemental Table 6, Supplemental Notes).

296 Consistent IBD microbial population structure discovered by unsupervised analysis

The existence of subtypes within gut microbial communities has been a major open question in human microbiome studies, and it is of particular importance within IBD as a potential explanation 299 for heterogeneity in disease etiology and treatment response^{6,9}. To systematically characterize 300 population structure in the IBD gut microbiome that was reproducible among studies, we 301 performed both discrete and continuous structure discovery on the 10 cohorts using our meta-302 analysis framework. To identify potential discrete community types (i.e. clusters), we performed 303 clustering analysis within each cohort's IBD patient population, and evaluated the clustering 304 strength via prediction strength (Methods). We found no evidence to support discrete clustering 305 structure within individual cohorts, nor were we able to reproduce each cohort's clustering results 306 externally (Fig. 5a). This lack of discrete structure was consistent when we further stratified 307 samples to either CD or UC populations (Supplemental Fig. 9), or extended to additional 308 dissimilarity metric and clustering strength measurements (Supplemental Fig. 9, Methods). Our 309 observation that the IBD gut microbiome cannot be well characterized by discrete clusters is thus 310 consistent with previous findings on gut microbial heterogeneity for healthy populations⁴⁰ and 311 suggests that, at the level powered by this study, such microbiome subtypes are not clearly 312 responsible for clinical heterogeneity.

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.31.261214; this version posted August 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.



314 Figure 5: Unsupervised population structure discovery finds no evidence of microbiome-based subtypes in 315 the IBD gut, but a reproducible gradient of continuously variable dysbiosis in disease. a) No support was 316 detected for discrete microbiome subtypes (clusters) within the IBD microbiome, neither within cohort nor when 317 evaluated among studies (red bars) using prediction strength⁴¹. This remained true during stratification within CD and 318 UC, and for additional dissimilarity metric/clustering strength measurements (Supplemental Fig. 9). b) Conversely, 319 two reproducible, continuously variable patterns of microbiome population structure were identified using groups of 320 similar principal components (Methods)³⁵. These patterns were consistent within and between cohorts, disease types, 321 and sample types, as well as under different edge strength cutoffs (Supplemental Fig. 11), and their consensus 322 loadings were reproducible among cohorts (Supplemental Fig. 12). c) Top 20 genera with highest absolute loadings 323 for the disease-associated dysbiosis score corresponding to the first cluster in b. Many of these taxa were also IBD-324 associated (Fig. 3b). d) Distribution of the dysbiosis pattern across CD, UC, non-IBD control, and healthy populations.

Although it was defined in an unsupervised way solely within the IBD population, across which the pattern is highly variable, it also differentiates well between IBD and control populations (**Supplemental Fig. 13**).

327 Conversely, we identified two consistent, continuously varying gradients of microbial community 328 variation in the IBD microbiome (Fig. 5b-d. Supplemental Fig. 10). These gradients represent 329 patterns of microbes that occur with greater or lesser abundance in tandem, and which covary 330 across subjects in a population; they were identified as principal component (PC) vectors that recur among different cohorts (see **Methods**)³⁵. Briefly, we used the four largest IBD cohorts (CS-331 332 PRISM, Pouchitis, PROTECT, and RISK) as training datasets to identify two clusters of consistent 333 PCs (Fig. 5b), which were confirmed with sensitivity analysis (Supplemental Fig. 11) and 334 validated in the remaining cohorts (Supplemental Fig. 12). The consensus loadings (i.e. within-335 cluster average) representing these two clusters (Fig. 5c, Supplemental Fig. 10, Supplemental 336 **Table 7**) were used to assign continuously varying scores to the IBD population that capture 337 gradient changes in the microbiome that occurred consistently within IBD, across diseases, 338 sample types, and cohorts. This disease-linked "type" of microbiome variation corresponded 339 roughly to severity or extent of inflammation, as detailed below.

340 In particular, while the second continuous population structure captured the Firmicutes-Bacteroidetes tradeoff present in most gut microbiome studies (Supplemental Fig. 10)^{9,26,40}, the 341 342 first continuous score was IBD-specific and corresponded roughly to more extreme disease-343 associated dysbiosis in CD and UC populations (Fig. 5d). This is evidenced by the taxa with highest weights in the scores' consensus loading vector (Fig. 5c), which included taxa 344 345 differentially abundant between IBD and control populations (Fig. 3). The score was consistent 346 both within CD and UC while also further differentiating IBD, non-IBD control, and healthy 347 populations (Fig. 5d, Supplemental Fig. 13), even though it was identified unsupervisedly only 348 from diseased subsets. The composition of the score and its population structure are also 349 consistent with our recent definition of dysbiotic gut microbiome configurations corresponding with

350 multi'omic perturbations during IBD activity⁹. Together with the supervised meta-analysis results 351 above, these unsupervised population structure findings confirm that there are no detectable 352 discrete subtypes of the gut microbiome in IBD even among ~5,000 combined samples, while 353 showing a single continuously variable gradient of microbiome changes reproducibly present 354 during more dysbiotic diseases.

355 **Discussion**

356 Here, we provide a novel framework for microbial community meta-analysis and apply it to the 357 first large-scale integration of over 5,100 amplicon profiles of the stool and mucosal microbiomes 358 in IBD. This identified a significantly reproducible gradient in the gut microbiome indicative of 359 increasing dysbiosis in subsets of patients. The study also showed no evidence of additional 360 population structure, such as microbiome-driven discrete disease subtypes, within CD or UC. The 361 increased power provided by meta-analysis supported many of the taxonomic associations 362 previously ascribed to IBD (e.g. Faecalibacterium, Ruminococcus, Enterobacteriaceae) while 363 uncovering new associations (Turicibacter, Acinetobacter) not confidently associated with 364 inflammation by other populations or data types. Almost all effects were exhibited similarly using 365 either stool or mucosal profiling, with a small number of exceptions showing significant 366 differentiation (e.g. Dehalobacterium). Novel disease-treatment response interactions were 367 observed (e.g. steroids on Enterobacteriaceae). Finally, the meta-analysis framework developed 368 for the study, MMUPHin, has been extensively evaluated and its performance for batch effect 369 removal, supervised meta-analysis of exposures and covariates, and unsupervised population 370 structure discovery validated on a variety of simulated microbial community types. It is extensible 371 to integration of microbial community taxonomic or functional profiles from other data types (e.g. 372 metagenomic sequencing) or environments.

373 However, all microbial community meta-analyses should be approached with caution, since in 374 many cases unwanted sources of technical variation between studies (i.e. batch effects) are so large as to potentially mask biological signals even after correction⁴⁹⁻⁵¹ (**Supplemental Notes**). 375 376 Reducing inter-study variation in microbial community profiles is challenging relative to other 377 'omics data types due to 1) the extreme heterogeneity of microbes within most communities 378 (exacerbating both technical and biological differences), and 2) feature zero-inflation arising from both biological and technical reasons^{13,52}. Notably, despite these challenges, MMUPHin was able 379 380 to meta-analyze amplicon profiles in this study both to associate microbial shifts with disease 381 outcome, to associate them with treatment-specific differences, and to identify a single pattern of 382 typical microbial variation within IBD. While previous efforts have developed IBD dysbiosis scores by contrasting patients with control groups^{7,9}, this pattern of microbial variation was present 383 384 specifically within IBD patients (both CD and UC), and in agreement with supervised methods, 385 captured several classes of microbial functional responses in the qut (Supplemental Note).

The IBD gut microbiome particularly stands to benefit from meta-analysis, as have other multiply-386 387 sampled conditions such as colorectal cancer^{53,54}, in order to identify ecological and 388 microbiological changes during the disease that are reproducible across populations. We consider 389 this study based on 16S rRNA gene sequencing to be a proof of concept, able to achieve 390 unprecedented power due to the number of amplicon profiled samples available, but with greater 391 precision possible in future work using e.g. metagenomic and other 'omics technologies. This also 392 enabled comparison of responses in the stool versus mucosal microbiomes, the latter of which 393 are not amenable to metagenomic profiling from biopsies; these were in overall good agreement, 394 but the few areas of significantly differential responses to inflammation are likely of particular 395 immunological interest. The large sample and population sizes also provide some confidence in 396 ruling out discrete, microbially-driven population subtypes as an explanation for CD and UCs' 397 clinical heterogeneity. Instead, the work identified a single consistent axis of gradient microbial 398 change corresponding to increasing departures from "normal" microbiome configurations^{7,9,55}. 399 This pattern of consistent microbial dysbiosis can continue to be explored in further work on its 400 functional, immunological, and clinical consequences. Overall, this study represents one of the 401 first large-scale, methodologically appropriate, targeted meta-analysis of the IBD microbiome, and 402 the corresponding methodology and its implementation are freely available for future meta-403 analyses of human-associated and environmental microbial populations.

404 Methods

405 MMUPHin: a uniform statistical framework for meta-analysis of microbial community 406 studies

We developed MMUPHin (Meta-analysis Methods with a Uniform Pipeline for Heterogeneity in microbiome studies) as a framework for meta-analysis of microbial community studies using taxonomic, functional, or other abundance profiles. It includes components for batch effect adjustment, differential abundance testing, and unsupervised discrete and continuous population structure discovery.

412 Batch adjustment

For microbial community batch correction, we extended the batch correction method developed for gene expression data in ComBat¹⁵ with an additional component to allow for the zero inflated nature of microbial abundance data. In our model, sample read count*Y* was modelled with respect to both batch variable and biologically relevant covariate(s) *X*:

417
$$Y_{ijp} = exp\{\beta_p X_{ij}' + \sigma_p(\gamma_{ip} + \delta_{ip}\epsilon_{ijp})\} \times I_{ijp}$$

Where *i* indicates batch/study, *j* indicates sample, and *p* indicates feature. γ_{ip} and δ_{ip} are batch-418 419 specific location and scale parameters. σ_p is a feature-specific standardization factor. β_p are covariate-specific coefficients, and ϵ_{ijp} is an independent error term following a standard normal 420 distribution. I_{ijp} is a binary (0, 1) zero-count indicator, to allow for zero inflation of features. As in 421 ComBat, γ_{ip} and δ_{ip} are modelled with normal and inverse-gamma priors, respectively. 422 423 Hyperparameters are estimated with empirical Bayes estimators as in ComBat¹⁵. The posterior means, $\widehat{\gamma_{ip}}$ and $\widehat{\delta_{ip}}$, along with standard frequentist estimates $\widehat{\beta_p}$ and $\widehat{\sigma_p}$ are used to provide 424 425 batch-corrected count data:

426
$$\widetilde{Y_{ijp}} = exp\{\frac{Y_{ijp} - \widehat{\beta_p}X_{ij}' - \widehat{\gamma_{ip}}\widehat{\sigma_p}}{\delta_{ip}^*} + \widehat{\beta_p}X_{ij}'\} \times I_{ijp}$$

Per-sample feature counts are then re-normalized to keep sample read depth unchanged postcorrection. In practice, the user provides sample microbial abundance table (Y), batch/study information, and optionally any other covariates X that are potentially confounded with batch but encode important biological information. MMUPHin outputs an adjusted profile \tilde{Y} that is corrected for the effect of batches but retains the effects of X (if provided).

432 <u>Meta-analysis differential abundance testing</u>

For meta-analytical differential abundance testing, after batch correction, MMUPHin first performs multivariate linear regression within individual studies using previously validated data transformation and modelling combinations appropriate for microbial community profiles (MaAsLin2³³). This yields study-specific, per-feature differential abundance effects estimations $\widehat{\beta_{ip}}$, where *i* indicates study and *p* indicates feature. These are then aggregated into metaanalysis effect size with fixed/random effects modelling as implemented in the metafor R package³⁴:

440
$$\widehat{\beta_{ip}} = \beta_p + \epsilon_{ip} + e_{ip}$$

441 β_p is the overall differential abundance effect of feature p. ϵ_{ip} is per-study measurement error, and e_{ip} is study-specific random effects term (not present in fixed-effect models). In practice, the 442 443 user provides a microbial community profile, study design (batch) information, the main exposure 444 variable of interest, and optional additional covariates. If any meta-analyzed studies include 445 repeated measures (e.g. longitudinal designs), then random covariates can also be provided and 446 will be modelled for such studies. MMUPHin then performs MaAsLin2 regression modelling within each study and aggregates effect sizes of the exposure variable $\widehat{\beta_{ip}}$ across studies using the 447 resulting random/fixed effects model. The estimated overall effect, $\widehat{\beta_p}$, is reported as the overall 448 differential abundance effect for feature p. 449

450 <u>Unsupervised discrete structure discovery</u>

451 For unsupervised discrete (i.e. cluster) structure discovery of a single study, again after batch correction, MMUPHin uses average prediction strength⁴¹, an established clustering strength 452 453 metric, to measure the existence of reproducible clusters among meta-analyzed datasets. Briefly, 454 for each individual dataset, the metric randomly and iteratively divides samples into "training" and 455 "validation" subsets. In each iteration, clustering is first performed on the training samples, across a range of cluster numbers k, yielding (for a specific k) training sample clusters $A_{k1}, A_{k2}, \dots, A_{kk}$. 456 457 Note that $A_{k1}, A_{k2}, ..., A_{kk}$ jointly forms a partition of the testing sample indices. The same 458 clustering analysis is then performed on the validation samples, and the resulting partition of 459 sample space provides classification membership potentially different from clustering 460 memberships $A_{k1}, A_{k2}, ..., A_{kk}$. Prediction strength for k clusters is defined as

462 = $\min_{1 \le l \le k} \frac{1}{n_{kl}(n_{kl}-1)} \sum_{j \ne j' \in A_{kl}} I$ {validation samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to training samples *j* and *j'* are classified to the same group according to

i.e. the minimum (across validation clusters) proportion of same-cluster sample pairs also being classified as the same group by training samples. $n_{kl} = |A_{kl}|$, or the number of test samples in the *l*th cluster.

Average prediction strength is the average of prediction strengths across randomization iterations. Intuitively, it characterizes the degree of agreement between the clustering structures in randomly partitioned validation and training subsets; if k is appropriately describing the true number of discrete clusters in the dataset, then average prediction strength should be close to one (training and validation samples agree most of the time).

We additionally generalized this metric to meta-analysis settings, where we aimed to quantify the agreement of clustering structures between studies. In the meta-analytical setting, generalized prediction strength for cluster number k in study i with validation study i' is

474 $gps_{ii'}(k)$

475 $= \min_{1 \le l \le k} \frac{1}{n_{ki;l}(n_{ki'l} - 1)} \sum_{j \ne j' \in A_{ki;l}} I\{\text{validation samples } i'j \text{ and } i'j' \text{ are classified to the same group according to study } i\}$

Where A_{kil} indicates the *l*-th cluster membership in study *i*, when cluster number is specified as $k; n_{kil} = |A_{kil}|$. The average generalized prediction in study *i* for cluster number *k* is then defined as the average of $gps_{iii}(k)$ across all $i' \neq i$, i.e., all validation studies (instead of iterations of randomized partitions). Similar to the single study prediction strength, it describes the generalizability of clustering structure in study *i* in external validation studies.

481 <u>Unsupervised continuous structure discovery</u>

We extended our previous work in cancer gene expression subtyping³⁵ to perform unsupervised 482 483 continuous structure discovery in microbial community profiles. Complementary to discrete cluster 484 discovery, the goal is to identify strong feature covariation signals (gradients) that are reproducible 485 across studies. This is carried out by performing principal component analysis individually in 486 microbiome studies and constructing a network of correlated PCA loading vectors, to identify 487 loadings that are consistently present across studies. In detail, given a collection of training 488 microbial abundance datasets, our method takes the following steps (visualized in **Supplemental** 489 Fig. 4):

- 490 1. For each dataset *i*, PCA is performed on normalized and arcsin square root-transformed 491 microbial abundance data. Given a user-specified threshold on variance explained, we 492 record its top PC loading vectors, $w_{i1}, w_{i2}, ..., w_{iJ_i}$, where J_i is the smallest number of top 493 loading vectors that jointly explain percentage of variability in the dataset past a 494 customizable threshold $0 < threshold_v < 1$ (default to 80%).
- 495 2. For two PC loadings from different datasets w_{ij} and w_{irjr} , similarity is quantified with the 496 absolute value of cosine coefficient⁵⁶ $|cos < w_{ij}, w_{irjr} > |$. This yields a network of PC 497 loading vectors associated by weighted edges w_{ij} and w_{irjr} , retaining edges only if their 498 weight surpasses a customizable similarity threshold ($|cos < w_{ij}, w_{irjr} > | >$ 499 *threshold*₅, 0 < *threshold*₅<1).

In the resulting network, we perform community detection⁵⁷ to identify densely connected
modules of PCs. Each module by definition consists of PCs from different datasets that
are similar to each other - whether or not they occur in the same order or with similar
percent variance explained - and which thu represent strong feature covariation signals
that are recurrent in studies.

4. For a module k containing PC set M_k , its consensus vector W_k is calculated as the

average of sign-corrected loading vectors in M_k , i.e., $W_k \coloneqq \frac{\sum_{w_{ij} \in M_k} \widetilde{w_{ij}}}{|M_k|}$. Note that the average is taken not over the original loading vectors w_{ij} , but rather their sign-corrected versions $\widetilde{w_{ij}}$. Specifically, the signs of each w_{ij} in M_k are corrected so that all of the loading vectors have positive cosine coefficients.

510 5. The module-wide consensus vectors W_k represent strong, mutually independent, and 511 reproducible covariation signals across the microbial datasets; they are used to identify 512 continuously varying gradients in microbial abundance profiles that represent reproducible 513 population structures. Specifically, given a sample with normalized and transformed 514 microbial abundance measurements x, its continuous score for module k is defined as 515 $x'W_k$, as in regular PCA.

516 6. If additional studies are available, the reproducibility of each W_k can be further examined 517 by correlating W_k with the top PC loadings in each such validation study. For each 518 additional study, W_k is considered to be validated in that dataset if its absolute cosine 519 coefficient with at least one of the dataset's top PCs surpasses the coefficient similarity 520 cutoff *threshold*_s; the number of top PCs to consider in the validation dataset loadings is 521 determined with the same cutoff *threshold*_v.

522 Simulation validation of MMUPHin

523 We performed extensive simulation studies (Fig. 2, Supplemental Fig. 5-8, Supplemental Table 524 2) to validate the performance of each component of MMUPHin. In all cases these employed 525 realistic microbial abundance profiles SparseDOSSA generated using 526 (http://huttenhower.sph.harvard.edu/sparsedossa). This is a model of microbial community 527 structure using a set of zero-inflated log-normal distributions fit to selected training data, in this case drawn from the IBD gut microbiome⁶. Controlled microbial associations with simulated 528

529 covariates can then (optionally) be spiked in. Note that although the assumed null distributions in 530 MMUPHin and SparseDOSSA are the same (zero-inflated log normal), the models of effects for 531 batch and biological variables are substantially different: MMUPHin assumes exponentiated 532 effects, while SparseDOSSA assumes re-standardized linear effects.

533 Specifically, SparseDOSSA models null microbial feature abundances using a zero-inflated log-534 normal distribution:

535
$$log(Y_{ip}) \sim N(\mu_p, \sigma_p^2) \times Bernoulli(\pi_p)$$

This is the same initial distributional assumption as the MMUPHin batch correction model, when there are no batch or covariates effects. However, for spiked-in associations with metadata (batch, biological variables, etc.), SparseDOSSA uses a different model. Given a simulated, pre-spikingin feature count vector Y_p with mean μ_p^Y and standard error σ_p^Y , as well as a metadata variable vector *X* with mean μ^X and standard error σ^X , the post-spiked-in feature count is set to:

541
$$\widetilde{Y_{ip}} = \frac{1}{1+\phi} \{Y_{ip} + \phi \times [\frac{(X_i - \mu^X)\sigma_p^Y}{\sigma^X} + \mu_p^Y]\}$$

542 where ϕ is a configurable spike-in strength parameter. By this definition, microbial features post-543 spike-in have the same mean and approximately the same variance as before, the only difference 544 being the added association with the metadata variable(s) used. This is to ensure the counts of 545 the modified feature are not dominated by the values of the target covariate, but instead 546 distributed similarly to real data. The SparseDOSSA association model thus differs from 547 MMUPHin's model in two substantial ways: i) MMUPHin's associations are defined within the 548 exponentiated component and are thus better described as a multiplicative effect, whereas 549 SparseDOSSA's effects are directly applied on untransformed data, and ii) SparseDOSSA 550 additionally ensures realistic data generation with the re-standardization procedure.

551 Thus, the only component of the SparseDOSSA model that requires fitting to training data is the aforementioned zero-inflated log-normal null distribution. In our analysis, this was always PRISM⁶, 552 553 while other parameters were specified across a wide range of combinations to simulate different 554 application scenarios. These include the effect sizes of the associated batch and biological 555 variables (i.e. the ϕ parameter), number of batches, sample sizes, as well as dimensionality (both 556 the total number of features and the percentage of features randomized to be associated with 557 batch/biological variables). For each combination of simulation parameters, we performed 20 558 random replications (i.e. running simulation/evaluation with the same parameters but different 559 random seeds). **Supplemental Table 2** presents the full list of parameter combinations.

560 Evaluating batch adjustment

561 For evaluation of MMUPHin's batch effect adjustment component, we simulated metadata that included batch (with varying total batch numbers 2, 4, 6, 8), a binary positive control (simulated 562 563 "biological" covariate), continuous positive control ("biological"), and negative control (binary, and 564 guaranteed to be non-associated with microbial features) variables. Microbial abundance data 565 was simulated to be associated with the batch and the two positive control variables at varying 566 effect sizes (1, 2, 5, 10 for batch variable and fixed at 10 for positive control variables), but not 567 with the negative control variable. We additionally varied the number of samples per batch (20 to 568 simulate multiple-batches in a single study scenario, 100 to simulate meta-analysis with moderate 569 sized studies and 500 to simulate large meta-analysis), total number of microbial features (n=200 570 and 1000), as well as the percentage of features associated with metadata (5%, 10%, and 20%) 571 (Supplemental Table 2).

572 Performance of batch correction methods was quantified by omnibus associations (PERMANOVA
573 R2) between the simulated microbial abundance data with the batch and positive control variables,
574 before and after batch correction. For ComBat¹⁵ and our method, batch correction was performed

with both positive control variables as well as the negative control variable as covariates.
MMUPHin successfully reduced the confounding batch effect, but retained the effect of positive
control variables, and did not inflate the effect of negative control variable (Fig. 2a, Supplemental
Fig. 5).

579 Evaluating meta-analytic differential abundance testing

580 We evaluated false positive rates (FPR) in particular for meta-analytic feature association testing, 581 specifically the null case in which there are no associations between microbial features and 582 covariates, but false associations can arise in the presence of batch effects with unbalanced 583 distribution of covariate values across studies (Fig. 2b). For simulation, we generated a binary 584 covariate unevenly distributed between two "studies" at varying levels of disparity (Supplemental 585 Table 2). Microbial abundance data was simulated to be associated only with the two studies and 586 not with the covariate (i.e. study confounded null data), with varying strengths of batch effect (from 587 0 to 10). The number of samples per batch varied between 100 and 500 to, again, simulate 588 moderate- and large-sized meta-analysis. Lastly, we varied total number of microbial features and 589 the percentage of features associated with metadata as above.

590 FPRs were calculated as the percentage of simulated microbial features with nominal p-values < 591 0.05 for associations with the exposure variable. Four data normalization and analysis regimes 592 were evaluated (Fig. 2c, Supplemental Fig. 6): a) naive MaAsLin2 model on the study effect confounded null data (without explicitly modelling the batches), b) the quantile normalization 593 594 procedure, paired with two-tailed Wilcoxon tests, as proposed in ¹⁸, c) BDMMA as proposed in ¹⁹, 595 with the default 1,0000 total MCMC sampling and 5,000 burn-in, d) the complete MMUPHin meta-596 analysis model for the batch corrected data as described above. Note that due to its computational 597 cost we were only able to evaluate the Dirichlet-multinomial regression model on a subset of 598 parameter combinations, namely number of samples per batch = 100, number of features = 200,

and percent of associated microbes = 5%. These parameters roughly agree with those used in the simulation analysis in the method's original publication¹⁹.

We also evaluated the computational costs of quantile normalization, BDMMA, and MMUPHin (**Supplemental Fig. 6**). For this, the same subset of 20 replications (batch effect 0, exposure imbalance 0, number of samples per batch 100, and number of features 200) were ran through the three methods under the same computation environment (single core Intel(R) Xeon(R) CPU E5-2680 v2 @ 2.80GHz).

606 Evaluating unsupervised discrete structure discovery

607 To simulate microbial abundance data with known discrete clustering structure, we again used 608 the simulation model above, with microbial feature associations added both with a discrete "batch" 609 variable and a discrete clustering variable, at varying number of batches (2, 4, 6, 8), number of 610 clusters (3, 4, 5, 6), as well as effect size of association (0 to 10 for batch, fixed at 10 for cluster). 611 For the evaluation of MMUPHin's unsupervised methods (both here and during continuous 612 population structure discovery below), we fixed the number of samples per batch at 500, the 613 number of total features at 1,000, and the percent of associated features at 20%. These were 614 guided by the fact that the underlying unsupervised methods (clustering, PCA) require larger 615 sample sizes for good performance even without batch confounding, and are generally only 616 practical with higher feature dimensions (Supplemental Table 2).

Performance of clustering was evaluated as the percentage of replicates in which the right number of synthetically defined underlying clusters was identified using prediction strength, across technical replicates for a fixed combination of simulation parameters. That is, the number of clusters within a simulation was identified as that which maximized prediction strength. This was compared to the "truth" (i.e. the known simulation parameter) and counted as a success only if the two agreed. The percentage of success for a given parameter combination across the 20 random replications was used as the evaluation metric for model performance. We compared the
performance of clustering before and after MMUPHin batch correction (Fig. 2e, Supplemental
Table 7). Note that batch correction is modelled only using the batch variable and specifically not
including the cluster variable as a covariate in the batch correction model above, as the underlying
cluster structure is unknown in non-synthetic unsupervised analyses settings.

628 Evaluating unsupervised continuous structure discovery

To simulate microbial abundance data with known continuously variable population structure, we spiked in feature associations with both a simulated batch covariate (4, 6, 8) and a continuously varying gradient (uniformly distributed between -1 and 1), at varying number of batches and effect size of both associations (as above). The number of samples per batch, total number of microbial features, and the percentage of features associated were fixed at the same values as above (Supplemental Table 2).

635 Performance of continuous structure discovery analysis was evaluated as the Spearman 636 correlation between the known simulated gradient score and the strongest continuously valued 637 population structure as identified by MMUPHin's continuous structure discovery method (above). 638 We again compared the performance of continuous score discovery on the batch confounded and 639 batch corrected data (Fig. 2g, Supplemental Fig. 8). Note that, as above, batch correction is 640 again modelled only using the batch variable and does not have any access to the synthetic continuous gradient, as any underlying continuous population structure is unknown during 641 642 unsupervised analyses settings.

643 Collection and uniform processing of ten IBD microbiome studies employing 16S rRNA

644 gene sequencing

645 <u>Study inclusion and raw sequence data</u>

We curated 10 published 16S rRNA gene sequencing (abbreviated 16S) gut microbiome studies of IBD for meta-analysis (**Table 1, Supplemental Table 1**). Demultiplexed raw sequences were either downloaded from EBI (Jansson-Lamendella and Herfarth) or available locally as previously generated (other eight studies). Metadata were obtained either directly from the sequence repository/manuscript (Herfarth, Jasson-Lamendella, HMP2, MucosalIBD, PROTECT, RISK), or from collaborators (BIDMC-FMT, CS-PRISM, LSS-PRISM, Pouchitis). This resulted in a total of 5,151 samples and 2,179 subjects available prior to processing and quality control.

653 <u>Metadata curation</u>

654 We manually curated subject- and sample-specific metadata across studies to ensure 655 consistency. Variables collected and curated include:

• Disease (CD, UC, control), universally available.

Type of controls (non-IBD, healthy). Control information was available directly for CS PRISM, Jansson-Lamendella, and Pouchitis, inferred from study design described in
 manuscript for Herfarth, HMP2, MucosalIBD, and RISK (all non-IBD controls), and not
 applicable for BIDMC-FMT, LSS-PRISM, and PROTECT (only has IBD subjects).

- Sample type (biopsy, stool), universally available.
- Body site of biopsy sample collection (ileum, colon, rectum), with more detailed
 classifications recorded separately in case of need. Mappings for the relevant datasets
 are:

665	• CS-PRISM: terminal ileum, neo-ileum, pouch are aggregated as ileum; cecum,
666	ascending/left-sided colon, transverse colon, descending/right-sided colon,
667	sigmoid colon were aggregated as colon; rectum classification was kept
668	unchanged.
669	• HMP2: ileum classification kept unchanged; cecum, ascending/right-sided colon,
670	transverse colon, descending/left-sided colon, and sigmoid colon were aggregated
671	as colon.
672	 MucosalIBD: all terminal ileum samples, aggregated to ileum.
673	• Pouchitis: terminal ileum, pouch, pre-pouch ileum aggregated as ileum; sigmoid
674	colon aggregated to colon.
675	• PROTECT: all rectum samples, classification kept unchanged.
676	• RISK: terminal ileum was aggregated to ileum; rectum kept unchanged.
677 •	Montreal classifications:
678	\circ Location for CDs (L1, L2, L3, and possible combinations), available for BIDMC-
679	FMT, CS-PRISM, Herfarth, Jansson-Lamendella, LSS-PRISM, and Pouchitis.
680	$\circ~$ Behavior for CDs (B1, B2, and B3), available for CS-PRISM, Herfath, Jansson-
681	Lamendella, LSS-PRISM, Pouchitis, and RISK.
682	$\circ~$ Extent for UCs (E1, E2, and E3), available for CS-PRISM, Jansson-Lamendella,
683	LSS-PRISM, Pouchitis, and PROTECT.
684 •	Age at sample collection (in years), available for BIDMC-FMT, CS-PRISM, Herfarth,
685	HMP2, LSS-PRISM, MucosalIBD, Pouchitis, PROTECT, RISK.
686 •	Age at diagnosis (in years). Directly available for CS-PRISM, HMP2, LSS-PRISM, and
687	Pouchitis, inferred as baseline age for PROTECT and RISK as these were new-onset
688	cohorts.
689 •	Race (White, African American, Asian / Pacific Islander, Native American, more than one
690	race, others). Directly available for CS-PRISM, Herfarth, HMP2, PROTECT, and RISK,

691 inferred from manuscript cohort description for Jansson-Lamendella (all Caucasian692 cohort).

- Gender (male/female). Available for BIDMC-FMT, CS-PRISM, Herfarth, HMP2, Jansson Lamendella, LSS-PRISM, MucosalIBD, Pouchitis, PROTECT,
- 695 Treatment variables, including antibiotics, immunosuppressants, steroids, and 5-ASA. 696 These variables were encoded as ves/no to indicate, approximately, currently receiving 697 them at the time of sampling. Additional information such as specific medication or delivery 698 method was recorded separately if available in case of need. We note the potentially 699 confounding difference in studies' definitions of treatment: for Pouchitis and PROTECT 700 authors defined antibiotics as receiving the treatment within the past month (30 days for 701 Pouchitis, 27 days for PROTECT), whereas for CS-PRISM, HMP2, LSS-PRISM, and RISK 702 such determination was not possible (antibiotics "yes" was defined as "currently taking"). 703 Likewise, we had no additional information to determine the time extent for the other three 704 treatments, beyond that according to metadata/publication, patients were "currently taking" 705 the treatment at sample collection.
- For a comprehensive list of curation mapping schema, please refer to our metadata curation
 repository: https://github.com/biobakery/ibd meta analysis.

708 <u>16S amplicon sequence bioinformatics and taxonomic profiling</u>

Sequences were processed, per-cohort, with the published, standardized bioBakery workflow⁵⁸ using the UPARSE protocol⁵⁹ (version v9.0.2132-64bit). For all studies, demultiplexed sequences were truncated at 200bp max length and filtered by maximum expected error of one⁵⁹. Operational taxonomic units (OTUs) were clustered at 97% identity and aligned using USEARCH with 97% identity to the Greengenes database 97% reference OTUs (version 13.8)⁶⁰ for taxonomy assignment. The resulting Greengenes identifiers for OTUs were used as basis for matching features (taxa) among cohorts.

716 Quality control

Across samples, a median of 81.51% reads / sample passed quality control filtering and were 717 718 successfully assigned to OTUs with Greengenes identifiers (Supplemental Fig. 1). These 8.921 719 raw OTUs aggregated to a total of 1,122 genera prior to quality control. We retained taxa that 720 exceeded 5e-5 relative abundance with at least 10% prevalent in at least one study; this criterion 721 generally removes spurious OTU assignments while retaining rare organisms if confidently 722 present in at least one study. Lastly, we also removed low read depth samples with less than 723 3,000 total sequences, which retained 78.34%-100% samples per cohorts (Supplemental Table 724 1). The final resulting taxonomic profile, used for all further analysis, aggregated into 249 total 725 genera spanning 4,789 samples (OTUs unclassified under a particular taxonomy level were 726 aggregated as "unclassified" feature under that taxon, e.g. "Enterbacteriaceae unclassified" 727 accumulates all OTUs' abundances under the family that could not be classified at the genus level.

728 Data availability

Quality controlled (truncated and filtered) sequences, Greengenes mapped OTU count profiles,
 and curated sample metadata are available at the Human Microbial Bioactives Resource Portal
 (http://portal.microbiome-bioactives.org).

732 Applying MMUPHin to IBD gut microbiome meta-analysis

For the resulting collection of microbiome studies, batch and study effects was performed using MMUPHin on both the genus level feature abundance profiles. For either taxonomic rank, batch (i.e., sequencing run) effect correction was first performed within individual studies (when batch/plate information was available, applicable to BIDMC-FMT, CS-PRISM, LSS-PRISM, MucosalIBD, and RISK). Microbial abundance profiles across all studies were then jointly corrected for study effects, while modelling disease status (IBD or control), disease (CD or UC), and sample type (biopsy or stool) as covariates. Reduction of batch and study effects was
evaluated by PERMANOVA R2 (Fig. 3a).

741 Association analyses

742 Omnibus testing of microbial composition associations

743 We used PERMANOVA tests (2.000 permutations) as implemented in the R package vegan³⁷ 744 using Bray-Curtis dissimilarities for all omnibus association tests of overall microbial community 745 structure with covariates (Fig. 3a). Where appropriate, R2s were calculated conditioning on the 746 necessary covariates; specifically, CD/UC Montreal classifications were conditional on CD/UC 747 samples respectively, treatment was conditional on IBD status, biopsy location was conditional 748 on a sample being a biopsy, and all covariates were conditional on being non-missing. Otherwise, 749 variables were tested marginally (that is, each as the sole variable in the model). Importantly, to 750 account for repeated measures within subjects for longitudinal studies, we adopted the blocked 751 permutation strategy as in ⁹, where per-sample measurements (sample type, biopsy location, 752 treatment) were permuted within subjects, and per-subject measurements (disease, 753 demographics) were permuted along with subjects (but within cohorts, relevant for the all-cohorts 754 evaluation). For a full list of the model and permutation strategies that this resulted in for our 755 analysis, please refer to **Supplemental Table 3**. Finally, per-variable p-values were adjusted with 756 Benjamini-Hochberg false discovery rate control on a per-study basis.

757 Per-feature meta-analysis differential abundance testing

To identify microbial features individually significantly associated with one or more covariates, we applied MMUPHin's differential abundance testing model as described above. Cohorts were first stratified by sample type (biopsy or stool) and, where appropriate, diseases (CD or UC) prior to model fitting. Arcsin square root-transformed genus level taxon abundances were tested for 762 covariate associations in individual cohort strata with multivariate linear modelling (linear random 763 intercept model adopted for longitudinal studies). Covariates used for adjustment include age, 764 gender, and race for disease variables, and additionally disease status for treatment variables. 765 Effect sizes across cohort strata were aggregated with a random effects model with restricted maximum likelihood estimation³⁴. P-values were FDR adjusted across features for each variable. 766 767 For the full list of models adopted as well as cohort stratification strategy, please refer to 768 Supplemental Table 3. Fig. 3b visualizes the aggregated meta-analysis effects; for individual 769 study results refer to Supplemental Table 4.

770 Testing for phenotypic severity within CD and UC patients

Meta-analytical testing of features associated with CD behavior and UC extent classifications
were performed with similar models (**Supplemental Table 3**). Specifically, within each study's
CD patients, the tests for contrasts B2 versus B1 and B3 versus B1 are performed by

Relative abundance ~ $\beta_0 + \beta_1 I$ {subject is B2} + additional covariates (subsetted to B1, B2 CDs)

Relative abundance ~ $\beta_0 + \beta_1 I$ {subject is B3} + additional covariates (subsetted to B1, B3 CDs)

The two β_1 coefficients, once aggregated with meta-analysis, were reported as the effect sizes shown in **Fig. 4a**, along with their FDR corrected q-values (adjusted across features for each test).

```
779 Relative abundance ~ \beta_0 + \beta_1 I{subject is B2 or B3} + \beta_2 I{subject is B3} + additional covariates
```

 β_2 in this model corresponds to the effect of B3 in addition to the overall contrasts between B23 versus B1. The meta-analysis aggregated p-values of these effects were reported as the differentiation between the most severe and "medium" severity phenotypes (vertical bars indicating significance in **Fig. 4a**). Note that FDR adjustment of this effect was performed across the subset of features with at least either B2 versus B1 or B3 versus B1 effect significant (i.e., the subset of features visualized in Fig. 4a). Equivalent models were adopted for contrasts between
extent categories of UC patients. Individual study results for the aggregated effects in Fig. 4a are
in Supplemental Table 5.

788 Interaction effects testing

To test for interaction effects with sample type and diseases, we fit meta-analysis moderator
 models³⁴ on the per cohort strata effects:

791
$$\widehat{\beta_{ip}} = \beta_{0p} + \beta_{1p}I\{\text{cohort strata } i \text{ is biopsy}\} + \epsilon_{ip} + e_{ip}$$

792
$$\widehat{\beta_{ip}} = \beta_{0p} + \beta_{1p} I \{\text{cohort strata } i \text{ is CD}\} + \epsilon_{ip} + e_{ip}$$

The moderator effects β_{1p} correspond to the interaction effect between the exposure under evaluation (disease, treatment, etc.) with the moderator variable. **Fig. 4b** visualizes the two example features, *Dehalobacterium* and Enterobacteriacea; al significant interactions as well as individual study effects are in **Supplemental Table 6**.

797 **Population structure analyses**

798 Discrete structure discovery

799 We performed discrete subtype discovery (i.e. "enterotyping"⁶¹) in IBD. CD. and UC populations 800 across studies (longitudinal studies subsetted to baseline samples), using MMUPHin's discrete 801 structure discovery component. Only studies with at least 33 samples were considered for 802 clustering analysis, as this was the sample size in the original enterotype paper²⁶. Specifically, 803 clustering was performed on Bray-Curtis dissimilarity by the partition-around-medoid method as 804 implemented in R package cluster; the same method was adopted in previous enterotyping efforts 805 including the original enterotype paper^{26,40}. Clustering was evaluated with prediction strength and 806 validated externally with MMUPHin's generalized prediction strength as described above. Across studies, we found no evidence to support a particular number of clusters within IBD, CD, or UC
populations (Fig. 5a, Supplemental Fig. 9), suggesting that the IBD microbiome does not have
discrete clusters.

We additionally extended our clustering evaluation analysis to other dissimilarity metrics (Jaccard, root Jensen-Shannon divergence) and clustering strength measurements (Calinski-Harabasz index, average silhouette width), which were also explored in previous efforts⁴⁰, Importantly, the original enterotype paper adopted root Jensen-Shannon divergence and Calinski-Harabasz index for cluster discovery. Across combinations of these additional dissimilarities and clustering strength metrics, we also found no evidence to support discrete clusters (**Supplemental Fig. 9**).

816 Continuous structure discovery

817 Continuous structure discovery was performed with MMUPHin's corresponding component. The 818 four largest studies (CS-PRISM, Pouchitis, PROTECT, RISK) were subsetted to baseline samples 819 (only relevant for PROTECT), stratified by CD/UC and biopsy/stool sample type, and used as the 820 training sets for MMUPHin. The minimum variance explained threshold (*threshold*,) was set to 821 default (80%), but we varied the PC similarity (evaluated by absolute cosine coefficient) 822 cutoff*threshold*_s between 0.5 and 0.8 to assess the sensitivity of the two identified PC clusters in 823 **Fig. 5b** (corresponding to *threshold*_s = 0.65). As we show in **Supplemental Fig. 11**, with a small 824 $threshold_s(0.5)$ PC networks become denser, with the two PC clusters in Fig. 4b forming key 825 components of two larger clusters; when $threshold_s$ is large (0.8) the network is sparser, with 826 only the most highly similar nodes of the two clusters forming smaller communities. We thus 827 concluded that the two identified clusters in Fig. 5b were not sensitive to the cosine coefficient 828 threshold, as they were recurrently identified in both smaller and larger cutoff scenarios.

829 Continuous structure validation

830 We validated the consistency of the two clusters' corresponding continuous scores in all IBD 831 cohorts, non-IBD and healthy control samples, as well as a randomly permuted mock study (as a 832 negative control). The reproducibility of each continuous score within a study was defined as the 833 maximum absolute cosine coefficient between the score's consensus loading (as provided by 834 MMUPHin) and the top three principal component loadings discovered independently within that 835 study. Note that the number of top principal components considered here was set to a fixed value 836 (three) instead of based on a percent variance cutoff as in the MMUPHin continuous structure 837 discovery stage. This is because in the two identified clusters in Fig. 5c, the latest included node 838 was PC3. The randomly permuted study consisted of 473 samples (median validation data sets 839 sample size) randomly selected from the entire meta-analysis collection, but each sample's 840 microbial abundance was independently permuted across features. This was to simulate a 841 "negative control" dataset where there should be no continuous population structures.

As we show in **Supplemental Fig. 12**, the dysbiosis score was well validated across studies, except for healthy control samples and the negative control dataset. The Firmicutes-versus-Bacteroidetes trade-off score, on the other hand, was reasonably well reproduced in all studies and particularly well-established in healthy samples, but, again, was not significantly detected in the negative control dataset.

847 Continuous score assignment

Assignment of continuous scores was straightforward given the two consensus loading vectors provided by MMUPHin. Within each study, arcsin square root-transformed relative abundances were centered per-feature, the transformed abundance matrix was then multiplied by each consensus loading via dot product to generate per-sample continuous scores. These scores were used for visualization as in **Fig. 4d** and **Supplemental Fig. 10**, as well as for testing the difference

- between CD, UC, non-IBD, and healthy control populations as in **Supplemental Fig. 13** We
- 854 provide the two consensus loadings in **Supplemental Table 7**; interested researchers can follow
- 855 these steps to assign the two continuous scores in other datasets.

856

857 **References**

- Hirschhorn, J. N. & Daly, M. J. Genome-wide association studies for common diseases
 and complex traits. *Nat Rev Genet* 6, 95-108, doi:10.1038/nrg1521 (2005).
- Lambert, J. C. *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* **45**, 1452-1458, doi:10.1038/ng.2802 (2013).
- 862 3 Franke, A. *et al.* Genome-wide meta-analysis increases to 71 the number of confirmed 863 Crohn's disease susceptibility loci. *Nat Genet* **42**, 1118-1125, doi:10.1038/ng.717 (2010).
- Anderson, C. A. *et al.* Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet* **43**, 246-252, doi:10.1038/ng.764 (2011).
- 5 Price, A. L. *et al.* Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* **38**, 904-909, doi:10.1038/ng1847 (2006).
- 869 6 Morgan, X. C. *et al.* Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome Biol* **13**, R79, doi:10.1186/gb-2012-13-9-r79 (2012).
- 871 7 Gevers, D. *et al.* The treatment-naive microbiome in new-onset Crohn's disease. *Cell Host*872 *Microbe* 15, 382-392, doi:10.1016/j.chom.2014.02.005 (2014).
- 873 8 Ananthakrishnan, A. N. Environmental risk factors for inflammatory bowel diseases: a 874 review. *Dig Dis Sci* **60**, 290-298, doi:10.1007/s10620-014-3350-9 (2015).
- 875 9 Lloyd-Price, J. *et al.* Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. *Nature* 569, 655-662, doi:10.1038/s41586-019-1237-9 (2019).
- Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 26, 2190-2191, doi:10.1093/bioinformatics/btq340 (2010).
- Rhodes, D. R. *et al.* Large-scale meta-analysis of cancer microarray data identifies
 common transcriptional profiles of neoplastic transformation and progression. *Proc Natl Acad Sci U S A* **101**, 9309-9314, doi:10.1073/pnas.0401994101 (2004).
- Li, H. Microbiome, Metagenomics, and High-Dimensional Compositional Data Analysis.
 Annual Review of Statistics and Its Application 2, 73-94, doi:10.1146/annurev-statistics 010814-020351 (2015).
- 88613Mallick, H. et al. Experimental design and quantitative analysis of microbial community887multiomics. Genome Biol 18, 228, doi:10.1186/s13059-017-1359-z (2017).
- Li, Y., Willer, C., Sanna, S. & Abecasis, G. Genotype imputation. *Annu Rev Genomics Hum Genet* 10, 387-406, doi:10.1146/annurev.genom.9.081307.164242 (2009).

Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression
data using empirical Bayes methods. *Biostatistics* 8, 118-127,
doi:10.1093/biostatistics/kxj037 (2007).

- Leek, J. T. & Storey, J. D. Capturing heterogeneity in gene expression studies by
 surrogate variable analysis. *PLoS Genet* 3, 1724-1735,
 doi:10.1371/journal.pgen.0030161 (2007).
- Leek, J. T. *et al.* Tackling the widespread and critical impact of batch effects in highthroughput data. *Nat Rev Genet* **11**, 733-739, doi:10.1038/nrg2825 (2010).
- 89818Gibbons, S. M., Duvallet, C. & Alm, E. J. Correcting for batch effects in case-control899microbiome studies. *PLoS Comput Biol* **14**, e1006102, doi:10.1371/journal.pcbi.1006102900(2018).
- 90119Dai, Z., Wong, S. H., Yu, J. & Wei, Y. Batch effects correction for microbiome data with902Dirichlet-multinomial regression.Bioinformatics35,807-814,903doi:10.1093/bioinformatics/bty729 (2019).
- Manichanh, C., Borruel, N., Casellas, F. & Guarner, F. The gut microbiota in IBD. *Nat Rev Gastroenterol Hepatol* 9, 599-608, doi:10.1038/nrgastro.2012.152 (2012).
- 806 21 Kostic, A. D., Xavier, R. J. & Gevers, D. The microbiome in inflammatory bowel disease:
 807 current status and the future ahead. *Gastroenterology* 146, 1489-1499, doi:10.1053/j.gastro.2014.02.009 (2014).
- Halfvarson, J. *et al.* Dynamics of the human gut microbiome in inflammatory bowel disease.
 Nat Microbiol 2, 17004, doi:10.1038/nmicrobiol.2017.4 (2017).
- Schirmer, M. *et al.* Compositional and Temporal Changes in the Gut Microbiome of
 Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. *Cell Host Microbe* 24,
 600-610 e604, doi:10.1016/j.chom.2018.09.009 (2018).
- Pasolli, E., Truong, D. T., Malik, F., Waldron, L. & Segata, N. Machine Learning Metaanalysis of Large Metagenomic Datasets: Tools and Biological Insights. *PLoS Comput Biol* 12, e1004977, doi:10.1371/journal.pcbi.1004977 (2016).
- Duvallet, C., Gibbons, S. M., Gurry, T., Irizarry, R. A. & Alm, E. J. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. *Nat Commun* 8, 1784, doi:10.1038/s41467-017-01973-8 (2017).
- Arumugam, M. *et al.* Enterotypes of the human gut microbiome. *Nature* 473, 174-180, doi:10.1038/nature09944 (2011).
- 922 27 Vazquez-Baeza, Y. *et al.* Guiding longitudinal sampling in IBD cohorts. *Gut* 67, 1743-1745,
 923 doi:10.1136/gutjnl-2017-315352 (2018).
- Morgan, X. C. *et al.* Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease. *Genome Biol* 16, 67, doi:10.1186/s13059-015-0637-x (2015).
- 927 29 Franzosa, E. A. *et al.* Gut microbiome structure and metabolic activity in inflammatory 928 bowel disease. *Nat Microbiol* **4**, 293-305, doi:10.1038/s41564-018-0306-4 (2019).
- 30 Liu, T. C. *et al.* Paneth cell defects in Crohn's disease patients promote dysbiosis. *JCI*30 *Insight* 1, e86907, doi:10.1172/jci.insight.86907 (2016).

- Hall, A. B. *et al.* A novel Ruminococcus gnavus clade enriched in inflammatory bowel
 disease patients. *Genome Med* 9, 103, doi:10.1186/s13073-017-0490-5 (2017).
- 933 32 Vaughn, B. P. *et al.* Increased Intestinal Microbial Diversity Following Fecal Microbiota
 934 Transplant for Active Crohn's Disease. *Inflamm Bowel Dis* 22, 2182-2190,
 935 doi:10.1097/MIB.00000000000893 (2016).
- 93633Mallick, H., Rahnavard, A. & McIver, L. Maaslin2: Maaslin2. R package version 1.2.0,937<u>http://huttenhower.sph.harvard.edu/maaslin2</u>.Bioconductor,938doi:10.18129/B9.bioc.Maaslin2 (2019).
- 939 34 Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. 2010 36, 48, doi:10.18637/jss.v036.i03 (2010).
- 941 35 Ma, S. *et al.* Continuity of transcriptomes among colorectal cancer subtypes based on 942 meta-analysis. *Genome Biol* **19**, 142, doi:10.1186/s13059-018-1511-4 (2018).
- 943 36 Huber, W. *et al.* Orchestrating high-throughput genomic analysis with Bioconductor. *Nat Methods* 12, 115-121, doi:10.1038/nmeth.3252 (2015).
- 945 37 Oksanen, J. *et al.* (2019).
- Vilhjalmsson, B. J. & Nordborg, M. The nature of confounding in genome-wide association
 studies. *Nat Rev Genet* 14, 1-2, doi:10.1038/nrg3382 (2013).
- 848 39 Ravel, J. *et al.* Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci U S A* 949 **108 Suppl 1**, 4680-4687, doi:10.1073/pnas.1002611107 (2011).
- 40 Koren, O. *et al.* A guide to enterotypes across the human body: meta-analysis of microbial
 951 community structures in human microbiome datasets. *PLoS Comput Biol* 9, e1002863,
 952 doi:10.1371/journal.pcbi.1002863 (2013).
- 95341Tibshirani, R. & Walther, G. Cluster Validation by Prediction Strength. Journal of954Computational and Graphical Statistics 14, 511-528, doi:10.1198/106186005X59243955(2005).
- Wold, S., Esbensen, K. & Geladi, P. Principal component analysis. *Chemometrics and intelligent laboratory systems* 2, 37-52, doi:10.1016/0169-7439(87)80084-9 (1987).
- Satsangi, J., Silverberg, M. S., Vermeire, S. & Colombel, J. F. The Montreal classification
 of inflammatory bowel disease: controversies, consensus, and implications. *Gut* 55, 749753, doi:10.1136/gut.2005.082909 (2006).
- 44 Lin, M. F. & Lan, C. Y. Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. *World J Clin Cases* 2, 787-814, doi:10.12998/wjcc.v2.i12.787 (2014).
- 45 Kevans, D. *et al.* Characterization of Intestinal Microbiota in Ulcerative Colitis Patients with
 and without Primary Sclerosing Cholangitis. *J Crohns Colitis* 10, 330-337,
 doi:10.1093/ecco-jcc/jjv204 (2016).
- 966 46 Presley, L. L., Wei, B., Braun, J. & Borneman, J. Bacteria associated with
 967 immunoregulatory cells in mice. *Appl Environ Microbiol* **76**, 936-941,
 968 doi:10.1128/AEM.01561-09 (2010).

- 96947Jones-Hall, Y. L., Kozik, A. & Nakatsu, C. Ablation of tumor necrosis factor is associated970with decreased inflammation and alterations of the microbiota in a mouse model of971inflammatory bowel disease. *PLoS One* **10**, e0119441, doi:10.1371/journal.pone.0119441972(2015).
- 973 48 Imhann, F. *et al.* Interplay of host genetics and gut microbiota underlying the onset and
 974 clinical presentation of inflammatory bowel disease. *Gut* 67, 108-119, doi:10.1136/gutjnl975 2016-312135 (2018).
- 976 49 Sinha, R. *et al.* Assessment of variation in microbial community amplicon sequencing by
 977 the Microbiome Quality Control (MBQC) project consortium. *Nat Biotechnol* 35, 1077-1086,
 978 doi:10.1038/nbt.3981 (2017).
- 97950Brooks, J. P. *et al.* The truth about metagenomics: quantifying and counteracting bias in98016S rRNA studies. *BMC Microbiol* **15**, 66, doi:10.1186/s12866-015-0351-6 (2015).
- Schloss, P. D. Identifying and Overcoming Threats to Reproducibility, Replicability,
 Robustness, and Generalizability in Microbiome Research. *MBio* 9,
 doi:10.1128/mBio.00525-18 (2018).
- 98452Tsilimigras, M. C. & Fodor, A. A. Compositional data analysis of the microbiome:985fundamentals, tools, and challenges. Ann Epidemiol 26, 330-335,986doi:10.1016/j.annepidem.2016.03.002 (2016).
- 53 Thomas, A. M. *et al.* Metagenomic analysis of colorectal cancer datasets identifies cross53 cohort microbial diagnostic signatures and a link with choline degradation. *Nat Med* 25,
 547-678, doi:10.1038/s41591-019-0405-7 (2019).
- 99054Wirbel, J. et al. Meta-analysis of fecal metagenomes reveals global microbial signatures991that are specific for colorectal cancer. Nat Med 25, 679-689, doi:10.1038/s41591-019-9920406-6 (2019).
- 99355Lloyd-Price, J. *et al.* Strains, functions and dynamics in the expanded Human Microbiome994Project. Nature **550**, 61-66, doi:10.1038/nature23889 (2017).
- 99556Jaskowiak, P. A., Campello, R. J. & Costa, I. G. On the selection of appropriate distances996for gene expression data clustering. BMC Bioinformatics 15 Suppl 2, S2,997doi:10.1186/1471-2105-15-S2-S2 (2014).
- 998 57 Csardi, G. & Nepusz, T. The igraph software package for complex network research.
 999 *InterJournal* Complex Systems, 1695-1695 (2006).
- 100058Mclver, L. J. *et al.* bioBakery: a meta'omic analysis environment. *Bioinformatics* **34**, 1235-10011237, doi:10.1093/bioinformatics/btx754 (2018).
- 100259Edgar, R. C. UPARSE: highly accurate OTU sequences from microbial amplicon reads.1003Nat Methods 10, 996-998, doi:10.1038/nmeth.2604 (2013).
- 100460McDonald, D. et al. An improved Greengenes taxonomy with explicit ranks for ecological1005and evolutionary analyses of bacteria and archaea. ISME J 6, 610-618,1006doi:10.1038/ismej.2011.139 (2012).
- 100761Costea, P. I. *et al.* Enterotypes in the landscape of gut microbial community composition.1008Nat Microbiol 3, 8-16, doi:10.1038/s41564-017-0072-8 (2018).

1009